Document is current
Any future updates will be listed below
-
Authors
Saliba, Daniel https://orcid.org/0009-0000-2681-2662
Osman, Eiman A.
Elmanzalawy, Abdelrahman
Saab, Christopher
Bui, Son
Hirka, Serhii
Anderson, Shaun
Toader, Violeta
Dore, Michael D. https://orcid.org/0000-0002-9721-3189
Rizzuto, Felix J. https://orcid.org/0000-0003-2799-903X
de Rochambeau, Donatien https://orcid.org/0009-0005-2850-5822
McKeague, Maureen https://orcid.org/0000-0002-3750-6027
Sleiman, Hanadi F. https://orcid.org/0000-0002-5100-0532
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
Canada Foundation for Innovation
Fonds de Recherche du Québec - Nature et Technologies
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
Canada Research Chairs
Médicament Québec Department of Chemistry, McGill University
McGill University
Medicament Quebec
Medicament Quebec McGill University
- License Information
-
More Information
Article History
Received: 17 October 2021
Accepted: 12 February 2026
First Online: 6 May 2026
Competing interests
: The Royal Institution for the Advancement of Learning/McGill University, Montreal (Canada) has filed a US patent application (application number US20230220381A1; status: pending) for the design of alenomers covering all experiments reported in this Article, excluding the work related to the Tras-binding aptamer, with H.F.S., D.d.R., M.M., S.H., D.S. and S.A. named as inventors. The other authors declare no competing interests.
